GHSI (Guardion Health Sciences) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Guardion Health Sciences is: No Data: Cannot be evaluated.

Competitive Comparison of Guardion Health Sciences's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardion Health Sciences's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Risk Assessment falls into.

Guardion Health Sciences (OTCPK:GHSI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Guardion Health Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardion Health Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (OTCPK:GHSI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098

Website

https://www.guardionhealth.com

Guardion Health Sciences Inc clinical nutrition company that develops and distributes clinically supported dietary supplements and medical foods. It offers a portfolio of science-based, clinically supported products designed to support consumers, healthcare professionals and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.

Executives

Bradley Louis Radoff	10 percent owner	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Katharine Joan Cox	officer: Chief Accounting Officer	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall	officer: CEO & President	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Family Foundation Radoff	other: See Footnote 1	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs	director	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes	director, officer: Chief Executive Officer	2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano	director	131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin	officer: Chief Accounting Officer	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan	officer: Chief Commercial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt	officer: Chief Financial Officer	1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans	director, officer: Chief Scientific Officer	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans	10 percent owner	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
John Townsend	other: Controller	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Gordon Bethwaite	officer: Vice Pres, Sales and Marketing	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128